Budesonide
- Generic Name
- Budesonide
- Brand Names
- Airsupra, Breyna, Breztri, Cortiment, Entocort, Pulmicort, Pulmicort Turbuhaler, Rhinocort, Symbicort, Tarpeyo, Uceris, Jorveza, Kinpeygo
- Drug Type
- Small Molecule
- Chemical Formula
- C25H34O6
- CAS Number
- 51333-22-3
- Unique Ingredient Identifier
- Q3OKS62Q6X
- Background
Budesonide is a glucocorticoid that is a mix of the 22R and 22S epimer used to treat inflammatory conditions of the lungs and intestines such as asthma, COPD, Crohn's disease, and ulcerative colitis.
Budesonide was granted FDA approval on 14 February 1994. It is also available in a combination product with formoterol.
- Indication
Budesonide extended release capsules are indicated for the treatment and maintenance of mild to moderate Crohn’s disease. Various inhaled budesonide products are indicated for prophylactic therapy in asthma and to reduce exacerbations of COPD. A budesonide nasal spray is available over the counter for symptoms of hay fever and upper respiratory allergies. Extended-release capsules are indicated to induce remission of mild to moderate ulcerative colitis and a rectal foam is used for mild to moderate distal ulcerative colitis. In addition, a delayed-release capsule formulation of budesonide is indicated to reduce proteinuria in adults with IgA nephropathy at risk of rapid disease progression. In Europe, budesonide is indicated to treat eosinophilic esophagitis (EoE) in adults.
- Associated Conditions
- Allergic Reaction, Allergic Rhinitis (AR), Asthma, Bronchoconstriction, Chronic Obstructive Pulmonary Disease (COPD), Collagenous Colitis, Crohn's Disease (CD), Eosinophilic Esophagitis, Exacerbation of asthma, Nasal Congestion, Nasal Polyps, Proteinuria, Pruritus, Rhino Sinusitis, Ulcerative Colitis, Vasomotor Rhinitis, Corticosteroid-responsive dermatoses, Mild Crohn’s Disease, Moderate Crohn’s Disease
- Associated Therapies
- Maintenance therapy
Treatment of Gastro-Intestinal and/or Hepatic Graft Versus Host Disease With Budesonide in Patients Following Peripheral Blood Stem Cell Transplantation
- Conditions
- Graft Vs Host Disease
- First Posted Date
- 2005-08-10
- Last Posted Date
- 2005-08-29
- Lead Sponsor
- Rafa Laboratories
- Target Recruit Count
- 24
- Registration Number
- NCT00128739
- Locations
- 🇮🇱
Hadassah Medical Organization,, Jerusalem, Israel
Aridol Challenge as a Tool to Predict Treatment Response to Inhaled Corticosteroids in COPD
- Conditions
- Lung Diseases, Obstructive
- First Posted Date
- 2005-07-04
- Last Posted Date
- 2016-04-20
- Lead Sponsor
- Syntara
- Target Recruit Count
- 140
- Registration Number
- NCT00117182
- Locations
- 🇦🇺
Mount Medical Centre, Perth, Western Australia, Australia
🇦🇺Wesley Medical Centre, Auchenflower, Queensland, Australia
🇦🇺Respiratory Clinic, Sydney, New South Wales, Australia
Study of Montelukast and Its Effect on Lower Leg Growth in Children With Asthma (MK-0476-254)
- Conditions
- Asthma, Bronchial
- Interventions
- Drug: Placebo to budesonide inhaler
- First Posted Date
- 2004-09-24
- Last Posted Date
- 2024-08-14
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 71
- Registration Number
- NCT00092092
Budesonide in Treating Former and Current Smokers With Bronchial Dysplasia
- Conditions
- Lung Cancer
- First Posted Date
- 2004-02-25
- Last Posted Date
- 2008-07-24
- Lead Sponsor
- British Columbia Cancer Agency
- Registration Number
- NCT00005880
- Locations
- 🇨🇦
British Columbia Cancer Agency, Vancouver, British Columbia, Canada
Pilot Study of Budesonide for Patients With Primary Sclerosing Cholangitis
- Conditions
- Cholangitis, SclerosingLiver Cirrhosis, Biliary
- Interventions
- First Posted Date
- 2000-02-25
- Last Posted Date
- 2017-05-31
- Target Recruit Count
- 22
- Registration Number
- NCT00004842
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
Childhood Asthma Management Program (CAMP) Phases I (Trial), II (CAMPCS), III (CAMPCS/2), and IV (CAMPCS/3)
- Conditions
- AsthmaLung Diseases
- Interventions
- First Posted Date
- 1999-10-28
- Last Posted Date
- 2014-04-03
- Lead Sponsor
- Johns Hopkins Bloomberg School of Public Health
- Target Recruit Count
- 1041
- Registration Number
- NCT00000575
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.